Chemotherapy as initial treatment in gliomatosis cerebri: Results with temozolomide

Netta Levin; John Moshe Gomori; Tali Siegal

doi:10.1212/01.WNL.0000130249.41341.58

Chemotherapy as initial treatment in gliomatosis cerebri: Results with temozolomide

Netta Levin^*
, John Moshe Gomori
, Tali Siegal

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known. Eleven radiotherapy-naive patients received a median number of 10 treatment cycles of temozolomide. An objective response was documented in 45%, and the median time to tumor progression was 13 months with a progression-free survival of 55% at 12 months. These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed.

Original language	English
Pages (from-to)	354-356
Number of pages	3
Journal	Neurology
Volume	63
Issue number	2
DOIs	https://doi.org/10.1212/01.WNL.0000130249.41341.58
State	Published - 27 Jul 2004
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1212/01.WNL.0000130249.41341.58

Cite this

@article{efecea2229bb4c6fb554624e5cbeaf31,

title = "Chemotherapy as initial treatment in gliomatosis cerebri: Results with temozolomide",

abstract = "The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known. Eleven radiotherapy-naive patients received a median number of 10 treatment cycles of temozolomide. An objective response was documented in 45\%, and the median time to tumor progression was 13 months with a progression-free survival of 55\% at 12 months. These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed.",

author = "Netta Levin and Gomori, \{John Moshe\} and Tali Siegal",

year = "2004",

month = jul,

day = "27",

doi = "10.1212/01.WNL.0000130249.41341.58",

language = "אנגלית",

volume = "63",

pages = "354--356",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Chemotherapy as initial treatment in gliomatosis cerebri

T2 - Results with temozolomide

AU - Levin, Netta

AU - Gomori, John Moshe

AU - Siegal, Tali

PY - 2004/7/27

Y1 - 2004/7/27

N2 - The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known. Eleven radiotherapy-naive patients received a median number of 10 treatment cycles of temozolomide. An objective response was documented in 45%, and the median time to tumor progression was 13 months with a progression-free survival of 55% at 12 months. These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed.

AB - The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known. Eleven radiotherapy-naive patients received a median number of 10 treatment cycles of temozolomide. An objective response was documented in 45%, and the median time to tumor progression was 13 months with a progression-free survival of 55% at 12 months. These results indicate that radiotherapy to extensive brain regions can be deferred until progressive disease is observed.

UR - https://www.scopus.com/pages/publications/3242780842

U2 - 10.1212/01.WNL.0000130249.41341.58

DO - 10.1212/01.WNL.0000130249.41341.58

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 15277636

AN - SCOPUS:3242780842

SN - 0028-3878

VL - 63

SP - 354

EP - 356

JO - Neurology

JF - Neurology

IS - 2

ER -

Chemotherapy as initial treatment in gliomatosis cerebri: Results with temozolomide

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this